Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Saved in:
| Title: | Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. |
|---|---|
| Authors: | Gisslinger H; Department of Internal Medicine I, Division of Haematology and Blood Coagulation, Medical University Vienna, Vienna, Austria. Electronic address: heinz.gisslinger@meduniwien.ac.at., Klade C; AOP Orphan Pharmaceuticals AG, Vienna, Austria., Georgiev P; University Multiprofile Hospital for Active Treatment 'Sveti Georgi', Clinic of Haematology, Medical University of Plovdiv, Plovdiv, Bulgaria., Krochmalczyk D; Teaching Unit of the Haematology Department, University Hospital in Krakow, Krakow, Poland., Gercheva-Kyuchukova L; Multiprofile Hospital for Active Treatment 'Sveta Marina', Clinical Haematology Clinic, Varna, Bulgaria., Egyed M; Department of Internal Medicine II, Kaposi MorCounty Teaching Hospital, Kaposvar, Hungary., Rossiev V; Samara Kalinin Regional Clinical Hospital, Samara, Russia., Dulicek P; Department of Clinical Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Illes A; Department of Haematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Pylypenko H; Department of Haematology, Regional Treatment and Diagnostics Haematology Centre, Cherkasy Regional Oncology Centre, Cherkasy, Ukraine., Sivcheva L; Multiprofile Hospital for Active Treatment-HristoBotev, First Department of Internal Medicine, Vratsa, Bulgaria., Mayer J; Clinic of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic., Yablokova V; Yaroslavl Regional Clinical Hospital, Department of Haematology, Yaroslavl, Russia., Krejcy K; AOP Orphan Pharmaceuticals AG, Vienna, Austria., Grohmann-Izay B; AOP Orphan Pharmaceuticals AG, Vienna, Austria., Hasselbalch HC; Department of Haematology, Zealand University Hospital, Roskilde, University of Copenhagen, Denmark., Kralovics R; Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Kiladjian JJ; Université de Paris, CIC 1427, Inserm, F-75010, Paris, France; Centre d'Investigations Cliniques, AP-HP, Hopital Saint-Louis, F-75010, Paris, France. |
| Corporate Authors: | PROUD-PV Study Group |
| Source: | The Lancet. Haematology [Lancet Haematol] 2020 Mar; Vol. 7 (3), pp. e196-e208. Date of Electronic Publication: 2020 Jan 31. |
| Publication Type: | Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32014125 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gisslinger+H%22">Gisslinger H</searchLink>; Department of Internal Medicine I, Division of Haematology and Blood Coagulation, Medical University Vienna, Vienna, Austria. Electronic address: heinz.gisslinger@meduniwien.ac.at.<br /><searchLink fieldCode="AU" term="%22Klade+C%22">Klade C</searchLink>; AOP Orphan Pharmaceuticals AG, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Georgiev+P%22">Georgiev P</searchLink>; University Multiprofile Hospital for Active Treatment 'Sveti Georgi', Clinic of Haematology, Medical University of Plovdiv, Plovdiv, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Krochmalczyk+D%22">Krochmalczyk D</searchLink>; Teaching Unit of the Haematology Department, University Hospital in Krakow, Krakow, Poland.<br /><searchLink fieldCode="AU" term="%22Gercheva-Kyuchukova+L%22">Gercheva-Kyuchukova L</searchLink>; Multiprofile Hospital for Active Treatment 'Sveta Marina', Clinical Haematology Clinic, Varna, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Egyed+M%22">Egyed M</searchLink>; Department of Internal Medicine II, Kaposi MorCounty Teaching Hospital, Kaposvar, Hungary.<br /><searchLink fieldCode="AU" term="%22Rossiev+V%22">Rossiev V</searchLink>; Samara Kalinin Regional Clinical Hospital, Samara, Russia.<br /><searchLink fieldCode="AU" term="%22Dulicek+P%22">Dulicek P</searchLink>; Department of Clinical Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Illes+A%22">Illes A</searchLink>; Department of Haematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.<br /><searchLink fieldCode="AU" term="%22Pylypenko+H%22">Pylypenko H</searchLink>; Department of Haematology, Regional Treatment and Diagnostics Haematology Centre, Cherkasy Regional Oncology Centre, Cherkasy, Ukraine.<br /><searchLink fieldCode="AU" term="%22Sivcheva+L%22">Sivcheva L</searchLink>; Multiprofile Hospital for Active Treatment-HristoBotev, First Department of Internal Medicine, Vratsa, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Mayer+J%22">Mayer J</searchLink>; Clinic of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Yablokova+V%22">Yablokova V</searchLink>; Yaroslavl Regional Clinical Hospital, Department of Haematology, Yaroslavl, Russia.<br /><searchLink fieldCode="AU" term="%22Krejcy+K%22">Krejcy K</searchLink>; AOP Orphan Pharmaceuticals AG, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Grohmann-Izay+B%22">Grohmann-Izay B</searchLink>; AOP Orphan Pharmaceuticals AG, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Hasselbalch+HC%22">Hasselbalch HC</searchLink>; Department of Haematology, Zealand University Hospital, Roskilde, University of Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Kralovics+R%22">Kralovics R</searchLink>; Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Kiladjian+JJ%22">Kiladjian JJ</searchLink>; Université de Paris, CIC 1427, Inserm, F-75010, Paris, France; Centre d'Investigations Cliniques, AP-HP, Hopital Saint-Louis, F-75010, Paris, France. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22PROUD-PV+Study+Group%22">PROUD-PV Study Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2020 Mar; Vol. 7 (3), pp. e196-e208. <i>Date of Electronic Publication: </i>2020 Jan 31. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32014125 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3026(19)30236-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e196 Titles: – TitleFull: Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gisslinger H – PersonEntity: Name: NameFull: Klade C – PersonEntity: Name: NameFull: Georgiev P – PersonEntity: Name: NameFull: Krochmalczyk D – PersonEntity: Name: NameFull: Gercheva-Kyuchukova L – PersonEntity: Name: NameFull: Egyed M – PersonEntity: Name: NameFull: Rossiev V – PersonEntity: Name: NameFull: Dulicek P – PersonEntity: Name: NameFull: Illes A – PersonEntity: Name: NameFull: Pylypenko H – PersonEntity: Name: NameFull: Sivcheva L – PersonEntity: Name: NameFull: Mayer J – PersonEntity: Name: NameFull: Yablokova V – PersonEntity: Name: NameFull: Krejcy K – PersonEntity: Name: NameFull: Grohmann-Izay B – PersonEntity: Name: NameFull: Hasselbalch HC – PersonEntity: Name: NameFull: Kralovics R – PersonEntity: Name: NameFull: Kiladjian JJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2020 Mar Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 2352-3026 Numbering: – Type: volume Value: 7 – Type: issue Value: 3 Titles: – TitleFull: The Lancet. Haematology Type: main |
| ResultId | 1 |
